Nvidia和Eli Lilly发射 1B AI 药物发现实验室 以缩短使用AI和机器人的开发时间 Nvidia and Eli Lilly launch $1B AI drug discovery lab to cut development time using AI and robotics.

Nvidia和Eli Lilly发起了一个为期五年的10亿美元的伙伴关系,在南旧金山建立一个AI联合创新实验室,目的是利用Nvidia的Vera Rubin芯片和BioNemo平台加速药物发现。 Nvidia and Eli Lilly have launched a $1 billion, five-year partnership to create an AI Co-Innovation Lab in South San Francisco, aiming to accelerate drug discovery using Nvidia’s Vera Rubin chips and BioNeMo platform. 该实验室将作为一个封闭循环系统运作,将人工智能驱动分子设计与机器人实验室合成和测试结合起来,缩短开发时间,从数年到几个月。 The lab will operate as a closed-loop system, combining AI-driven molecule design with robotic lab synthesis and testing to cut development time from years to months. 该倡议在J.P.摩根保健会议上宣布,反映了向作为核心科学协作者的AI的转变,并以可审计的决定途径支持林业发展局的透明度要求。 The initiative, announced at the J.P. Morgan Healthcare Conference, reflects a shift toward AI as a core scientific collaborator and supports FDA transparency requirements with auditable decision paths. 该实验室还将开发数字双胞胎,以改进生产,特别是GLP-1药物的制造,并标志着在整个药物开发生命周期内整合人工智能的一个重大步骤。 The lab will also develop digital twins to improve manufacturing, particularly for GLP-1 drugs, and marks a major step in integrating AI across the entire drug development lifecycle.